Fig. 1

Presence of L1 ORF1p in neutrophils from SLE patients. A Flow cytometry of PMN from a representative SLE patient with active disease stained for ORF1p and the lineage markers CD66b (middle row) and CD14 (bottom row) compared to cells stained with all antibodies except ORF1p (FMO, fluorescence minus one). B Flow cytometry of PBMC from the same SLE patient stained for ORF1p and the lineage markers CD19 (middle row) and CD14 (bottom row) compared to FMO controls. C Summary of the percent ORF1p + leukocytes in 13 SLE patients: neutrophils (CD66b⁺ PMN), low-density granulocytes (CD66b⁺ PBMC), B cells (CD19 + PBMC), T cells (CD3⁺ PBMC), and monocytes (CD14⁺ PBMC). Error bars represent standard deviation. D. Summary of the percent ORF1p⁺ leukocytes in 6 healthy controls (HC) in the same cell lineages. E The percent ORF1p⁺ neutrophils (open circles), low-density granulocytes (filled circles), and B cells (filled triangles) in patients with low SLEDAI < 4 (n = 4; -lo) and patients with high SLEDAI > 6 (n = 9; -hi). F Linear regression analysis of the percentages of ORF1p⁺ neutrophils (open circles), low-density granulocytes (filled circles), and B cells (filled triangles) versus SLEDAI of each patient